314054-00-7
中文名稱
N-(4-碘苯基)-5-硝基呋喃-2-甲酰胺
英文名稱
N-(4-iodophenyl)-5-nitrofuran-2-carboxamide
CAS
314054-00-7
分子式
C11H7IN2O4
分子量
358.09
MOL 文件
314054-00-7.mol
更新日期
2024/12/15 19:35:20
314054-00-7 結(jié)構(gòu)式
基本信息
中文別名
化合物C-176N-(4-碘苯基)-5-硝基-2-呋喃甲酰胺
英文別名
C-176STING inhibitor 1
C-176 STING inhibitor
N-(4-iodophenyl)-5-nitro-2-furamide
N-(4-iodophenyl)-5-nitrofuran-2-carboxamide
2-Furancarboxamide, N-(4-iodophenyl)-5-nitro-
所屬類別
生物化工：抑制劑物理化學(xué)性質(zhì)
沸點(diǎn)361.2±37.0 °C(Predicted)
密度1.935±0.06 g/cm3(Predicted)
儲存條件2-8°C(protect from light)
儲存條件Keep in dark place,Sealed in dry,2-8°C
溶解度溶于DMSO（高達(dá)25mg/ml）
酸度系數(shù)(pKa)11.14±0.70(Predicted)
形態(tài)固體
顏色棕色或黃色
穩(wěn)定性可在-20°C的DMSO中的溶液下儲存長達(dá)3個月。
N-(4-碘苯基)-5-硝基呋喃-2-甲酰胺價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | S6575 | N-(4-碘苯基)-5-硝基呋喃-2-甲酰胺 C-176 (STING inhibitor) | 314054-00-7 | 5mg | 877.13元 |
| 2024/11/08 | HY-112906 | N-(4-碘苯基)-5-硝基呋喃-2-甲酰胺 C-176 | 314054-00-7 | 5mg | 1000元 |
| 2024/11/08 | S6575 | N-(4-碘苯基)-5-硝基呋喃-2-甲酰胺 C-176 (STING inhibitor) | 314054-00-7 | 10mM(1mL in DMSO) | 997元 |
常見問題列表
生物活性
STING inhibitor C-176是一種有效的STING抑制劑。STING是細(xì)胞內(nèi)DNA感應(yīng)通路的主要信號分子。靶點(diǎn)
| Target | Value |
|
STING
() |
體外研究
C-176 strongly reduces STING-mediated, but not RIG-I- or TBK1-mediated, IFNβ reporter activity. Pretreatment with C-176 markedly reduce the CMA-mediated induction of serum levels of type I IFNs and IL-6.
體內(nèi)研究
C-176 (750/375 nmol C-176 per mouse in 200 μL corn oil) significantly reduces the CMA-mediated induction of serum levels of type I IFNs and IL-6., without significant toxicity.
C-176 results in a significant reduction in serum levels of type I IFNs and in a strong suppression of inflammatory parameters in the heart, with no evident signs of overt toxicity Trex1
?/?
mice.
C-176 demonstrates marked amelioration of various signs of systemic inflammation in Trex1
?/?
mice.
| Animal Model: | WT type mice. |
| Dosage: | 750/375 nmol C-176 per mouse in 200 μL corn oil (~1.34/0.67 mg/mL). |
| Administration: | Intraperitoneally, once. |
| Result: | Significantly reduced Serum levels of type I IFNs and IL-6. |